Financings in the biopharma sector were decidedly better in the third quarter compared to their dismal showing during the second quarter. The total generated from public and private transactions were well over double the amount that was raised in the second quarter. In the period, investor confidence returned, fueling a broad market rally after its tumble following Brexit and that helped the biotech sector. The strong showing has helped bring the year-to-date financings to $25 billion.)